Part, Chapter, Paragraph
1 I, 2. 10. 1| development of new genetic tests, DNA chip technologies and
2 II, 5. 1. 2| technical dimensions; lab tests, x-rays, hospital care,
3 II, 5. 5. 3| more specific diagnostic tests has perhaps contributed
4 II, 5. 5. 3| with normal~ diagnostic tests (3 months)~ Sporadic seizures (
5 II, 5. 5. 3| outpatient care, drug costs and tests], non-medical costs [services,
6 II, 5. 5. 3| There are no pathognomonic tests for the diagnosis of MS.
7 II, 5. 7. 1| detected via simple biochemical tests including a creatinine-based
8 II, 5. 8. 5| examination, lung function tests, imaging techniques and
9 II, 5. 9. 4| allergen to the battery of tests increased the overall estimated
10 II, 5. 9. 4| sensitization using skin prick tests. However, comparisons between
11 II, 5. 9. 4| allergen as measured by skin tests was established using the
12 II, 5. 9. 4| countries, underwent skin tests for allergy to nine common
13 II, 5. 9. 4| allergen as assessed by skin tests.~ ~Table 5.9.5. High or
14 II, 5. 9. 4| centre as assessed by skin tests~ ~ ~ ~Centre~d1~e1~g6~m2~
15 II, 5. 9. 4| allergy skin and in-vitro tests were available. 11.1% suffered
16 II, 5. 9. 4| ECRHS, underwent skin prick tests and serological assays)
17 II, 5. 9. 4| target cells. Provocation tests will then be carried out
18 II, 5. 9. 4| the results of the various tests and to the epidemiological
19 II, 5. 10. 2| intolerance) and/or sensitization tests (e.g., skin prick tests,
20 II, 5. 10. 2| tests (e.g., skin prick tests, specific IgE tests) rather
21 II, 5. 10. 2| prick tests, specific IgE tests) rather than gold standard
22 II, 5. 10. 2| Questionnaires and sensitization tests tend to overestimate the
23 II, 5. 11. 3| 97 and 2000–02 the patch tests revealed percentages of
24 II, 5. 11. 3| development of standardized patch tests, in vitro predictive tests,
25 II, 5. 11. 3| tests, in vitro predictive tests, in vitro skin absorption
26 II, 5. 12. 2| on a log scale), and then tests whether one or more joinpoints (
27 II, 5. 12. 7| Midthune DN (2000): Permutation tests for joinpoint regression
28 II, 6. 3. 1| need to know the number of tests performed, not just the
29 II, 6. 3. 1| not just the number of tests found positive.~ ~The annual
30 II, 6. 3. 3| became rare, as routine HCV tests became more available.~After
31 II, 6. 4. 5| diagnostic and susceptibility tests. A need has also been identified
32 II, 8. 2. 1| conditions through simple tests.~ ~Health risks of people
33 II, 8. 2. 1| to prematurity.~Certain tests, such as ultrasound, amniocentesis,
34 II, 8. 2. 1| sampling, and various blood tests, can be performed during
35 II, 9. 3. 1| referred for non-invasive tests, and fewer women than men
36 III, 10. 2. 4| development of new genetic tests, DNA chip technologies and
37 III, 10. 2. 4| laboratories can perform the tests. For the multifactorial
38 III, 10. 2. 4| differentiation between predictive tests (i.e., tests with 0-100%
39 III, 10. 2. 4| predictive tests (i.e., tests with 0-100% probability
40 III, 10. 2. 4| diseases) on the one hand and tests for diseases with high penetrance (
41 III, 10. 4. 2| However, the number of tests to be performed is not specified.
42 III, 10. 4. 5| Under the Directive, the tests for bathing waters have
43 III, 10. 4. 5| instead of the 19 different tests used previously. This simplification
44 III, 10. 4. 5| reduced. There will be more tests carried out more frequently
45 III, 10. 4. 5| show the quality of recent tests. Under this new regime,
46 III, 10. 5. 1| increased speed at different tests in 10-12 y old pupils (Wargocki
47 IV, 11. 1. 5| how and when particular tests and treatments should be
48 IV, 11. 5. 3| carrying out the different tests is a binding requirement
49 IV, 11. 5. 3| guidelines.~The use of authorised tests for testing the donors is
50 IV, 11. 5. 3| 16 shows the biological tests used in the countries and
51 IV, 11. 5. 3| indicates whether these tests are carried out on a routine
52 IV, 11. 5. 3| Figure 11.16. Biological tests in organ transplant~ ~As
53 IV, 11. 5. 3| in the use of a number of tests (Anti HIV, Anti HCV, Ag-Hbs
54 IV, 11. 5. 3| this does not apply to all tests (HTLV, Toxoplasmosis or
55 IV, 11. 5. 3| countries carry out these tests on a routine basis.~ ~Figure
56 IV, 12. 5 | conducting exercises and tests of, evaluating and revising
57 IV, 12. 10 | included information about the tests to be performed for the
